---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-052077"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:15:22.416687+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports Q2 FY2026 net loss $19.4M; PALISADE-3 Phase 3 complete, topline due Q4 2025

## Summary
- Net loss $19.4M vs $13.0M YoY; R&D expense $15.9M (up 56% YoY) on PALISADE program.
- PALISADE-3 Phase 3 trial of fasedienol for social anxiety disorder completed; topline data expected by Q4 2025.
- PALISADE-4 Phase 3 trial topline expected H1 2026; same public speaking challenge design.
- Cash, equivalents, and marketable securities $77.2M as of Sep 30, 2025.
- Paul Edick appointed to board of directors, effective October 2025.

## SEC filing metadata
- accession: 0001628280-25-052077
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/0001628280-25-052077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/vtgn-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-052077
- JSON: https://secwatch.observer/filing/0001628280-25-052077.json
- Plain text: https://secwatch.observer/filing/0001628280-25-052077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.